TTENK/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

TTENK/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Groups
  • Trending
  • News

More

  • Pricing
  • Community
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice.TENK is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities TENK rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. TENK/calls is an independent service and is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

TTENK/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Pulling SEC filings + quote and writing the call…

TTENK/calls
The BriefMarketsAll StocksNewsScreenerCommunity
← New search
Home›Stocks›CVR
CVR logo

CVR

CHICAGO RIVET & MACHINE CO

Next earnings Aug 6, 2026

Avoid
$10.33
▲ +0.17%
$10.33▼ -15.70%
over 1Y
L $8.67H $14.63
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+0.2%
1W+0.5%
1M+0.8%
3M+0.9%
YTD-26.1%
1Y-15.7%
OverviewFinancialsValuationQualityTimelineFilings
Rating
Avoid
Quality
C
Valuation
Fair value
Filings
Flagged
Avoid
Conviction
Horizon
Long (>12mo)

Going-concern doubt, five-year revenue slide and cash burn make CVR a turnaround lottery ticket, not an investable microcap.

Net income -$1.08M · FY2025

Chicago Rivet is a sub-$10M microcap fastener maker with a flashing red light on the cover of its own 10-K: the auditor and management explicitly disclose "substantial doubt about our ability to continue as a going concern," driven by recurring operating losses, negative operating cash flow, and declining liquidity. That is the single most important fact here and it dominates the fundamentals. Revenue has slid from $34.0M in FY2021 to $27.9M in FY2025, and the company has now posted three straight annual net losses (-$4.40M, -$5.62M, -$1.08M). Operating cash flow was -$1.23M in FY2025 against just $1.72M of cash on hand (down 10.6% YoY) — roughly a year of runway at the current burn, which is exactly why the going-concern flag exists.

The balance sheet is the only thing keeping this from being a zero: no long-term debt, liabilities/equity of just 0.24x, and $18.8M of stockholders' equity versus a $9.98M market cap — the stock trades at roughly half book. That's a genuine deep-value hook, and there are real signs of stabilization: the FY2025 net loss narrowed 80.7%, gross margin recovered to 14.8% (gross profit up 289%), COGS fell $2.16M, admin expense fell $562K, and Q4 sales jumped 46% YoY. Management's Albia-into-Tyrone consolidation and pricing/efficiency actions are showing up in the numbers.

AI-generated analysis, produced by our proprietary engine from SEC filing data.

Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jul 4, 2026, 1:40 AM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.

Is CVR a buy? The one-page verdict, explained →

Financials · annual, by fiscal year

Line itemFY21FY22FY23FY24FY25
Revenue$34.0M$33.6M$31.5M$27.0M$27.9M
Gross profit$6.47M$3.82M-$600K$1.06M$4.13M
Operating income$1.36M$3.56M-$5.84M-$5.16M-$1.20M
Net income$1.11M$2.87M-$4.40M-$5.62M-$1.08M
Diluted EPS—————
Net margin3.3%8.5%-14.0%-20.8%-3.9%

Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.

Key statistics

Valuation

Enterprise value$8.26M
EV / EBITDA—
EV / Sales0.3
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-10.9%
FCF yield-15.6%

Quality & risk

ROIC (est.)-5.0%
Free cash flow-$1.56M
Total debt$0.00
Net cash$1.72M
Altman Z-Score4.15 safe
Piotroski F-Score4/8

Capital returns

Buyback yield—
Dividend yield (est.)1.2%
Shareholder yield1.2%
Shares Δ YoY+0.0%

Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.

Disclosure timeline

SEC · 8-Ks + reports
Recent disclosure tone has skewed negative — read the flagged items.
  1. 8-K Shareholder vote2026-05-14

    Annual meeting votes certified plus routine other-event disclosure; no financial change

  2. 10-Q Quarterly report2026-05-08

    Q1 FY26 follows Q4's +46% sales rebound, but going-concern doubt still persists

  3. DEF 14A Proxy statement2026-04-03

    Proxy for 2026 annual meeting; director slate and routine governance items

  4. 10-K Annual report2026-03-24

    Going-concern doubt disclosed; FY25 loss narrowed to $1.08M, revenue +3%, margin up

  5. 10-Q Quarterly report2025-11-07

    Q3 FY25: OEM/dealer inventory cuts accelerated, pressuring fastener volumes

  6. 10-Q Quarterly report2025-08-08

    Q2 FY25: pricing/efficiency gains offset soft auto volumes; loss narrowing

  7. 8-K/A Amended 8-K2025-06-10

    Amended 8-K completing auditor-change disclosure (predecessor letter)

  8. 8-K Auditor change2025-06-02

    Changed independent auditor — a governance flag amid going-concern conditions

  9. 8-K Shareholder vote2025-05-15

    2025 annual meeting voting results reported; directors elected as proposed

Recent filings

all on EDGAR ↗
4Period ending 2026-05-192026-05-21open ↗8-KPeriod ending 2026-05-122026-05-14open ↗SDFiling2026-05-14open ↗10-QPeriod ending 2026-03-312026-05-08open ↗DEF 14APeriod ending 2026-04-022026-04-03open ↗ARSPeriod ending 2025-12-312026-04-03open ↗10-KPeriod ending 2025-12-312026-03-24open ↗SCHEDULE 13DFiling2025-12-29open ↗4Period ending 2025-12-122025-12-16open ↗3Period ending 2025-12-112025-12-16open ↗SCHEDULE 13DFiling2025-12-12open ↗10-QPeriod ending 2025-09-302025-11-07open ↗

Quality score

C
ValueGrowthProfitHealthMom.
ValueA+
GrowthB+
ProfitabilityF
Financial healthB-
MomentumF
  • ✓Revenue growing year-over-year
  • ✗Profitable (positive net income)
  • ✗Net margin above 10%
  • ✗Return on equity above 15%
  • ✓Liabilities below 2× equity
8.6752-week14.63
Revenue
$27.9M
+3.3% YoY
Net margin
-3.9%
ROE
-5.8%
P/E
—

SEC fundamentals · FY 2025

'21'22'23'24'25

■ revenue · ■ net income, by fiscal year

Revenue$27.9M+3.3%
Net income-$1.08M+80.7%
Gross profit$4.13M+289.2%
Operating income-$1.20M+76.8%
Cash & equivalents$1.72M-10.6%
Total assets$23.3M-0.3%
Total liabilities$4.47M+33.9%
Stockholders' equity$18.8M-6.0%
Gross: 14.8%Op.: -4.3%L/E: 0.24x

Frequently asked

Is CHICAGO RIVET & MACHINE CO (CVR) a buy?
CVR currently carries a Avoid rating with 4/5 conviction, derived from its latest SEC filings. Going-concern doubt, five-year revenue slide and cash burn make CVR a turnaround lottery ticket, not an investable microcap.
What is CHICAGO RIVET & MACHINE CO's quality score?
CVR scores 58.59809573955453/100 (grade C) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.

Sources: SEC EDGAR (CIK 0000019871, latest 10-Q filed 2026-05-08) · EODHD · Proprietary analysis · as of 7/4/2026, 5:40:34 AM.

Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.

Insider activity

Form 4 · SEC

Last 90 days: 1 open-market buy · 0 sales

2026-05-19
Cooney Kent H
Director
Buy900.00 @ $9.85$8.87K
2025-12-12
MORRISSEY JOHN A
10% owner
Buy2.54K @ $14.36$36.4K
2014-03-17
Showel John L
Director
Sell3.00 @ $39.01$117.03
2013-03-18
Showel John L
Director
Sell4.00 @ $22.00$88.00
2010-11-30
Bourg Michael J
Director
Buy300.00 @ $17.75$5.33K
2009-11-30
Bourg Michael J
Director
Buy500.00 @ $14.47$7.24K
2009-11-30
Cooney Kent H
Director
Buy100.00 @ $14.50$1.45K
2004-05-12
Divane William T Jr
Director
Buy1.00K @ $29.20$29.2K
2004-05-12
Divane William T Jr
Director
Buy1.00K @ $29.25$29.3K

Dividends

Semi-annual
Yield (TTM)
0.9%
Annual / share
$0.09
Last ex-date
2026-03-06
Last amount
$0.03
ex 2026-03-06paid 2026-03-20$0.03
ex 2025-12-05paid 2025-12-19$0.03
ex 2025-09-05paid 2025-09-19$0.03
ex 2025-06-05paid 2025-06-20$0.03
ex 2025-03-05paid 2025-03-20$0.03
ex 2024-12-05paid 2024-12-20$0.03

Source: EODHD. Yield = trailing-12-month dividends ÷ price.

Earnings history

beat/miss · move
2012-11-07—▲ 0.00%8-K ↗
2012-08-15—▲ +0.26%8-K ↗
2012-05-08—▼ -0.74%8-K ↗
2012-03-30—▲ +1.90%8-K ↗
2011-11-14—▲ +1.24%8-K ↗
2011-08-10—▲ +0.31%8-K ↗

Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.

Recent news

market news →
Chicago Rivet & Machine GAAP EPS of $1.12, revenue of $27.8MBearish
seekingalpha.com· 2026-03-25
Goldman: Oil market shock hits jet fuel, diesel harder; PBF, Par Pacific rated strong buy by Quant ratingsBearish
seekingalpha.com· 2026-03-17
Notable healthcare headlines for the week: Viatris, Novo Nordisk, and Gilead Sciences in focusBullish
seekingalpha.com· 2026-03-01
Cycle Pharmaceuticals acquiring Applied TherapeuticsBullish
seekingalpha.com· 2025-12-11
Chicago Rivet & Machine GAAP EPS of $0.07, revenue of $7.36M
seekingalpha.com· 2025-11-07
Oil and Gas Sector Strategies in Renewable Fuels Industry 2025-2030: Companies are Exploring Co-processing Pathways for Efficient, Low-cost Production IncreasesBullish
globenewswire.com· 2025-10-31

Vs tracked universe

compare →

1195 tracked peers · median

TENK Score59 vs 67
Revenue growth3.3% vs 7.5%
Net margin-3.9% vs 10.0%
Return on equity-5.8% vs 12.0%
P/E— vs 26.2